We recently compiled a list of the 10 Companies Echo Friday’s Market Pessimism. In this article, we are going to take a look ...

Neurocrine Biosciences Q4 earnings topped forecasts, but revenue slightly missed. Analysts see Ingrezza's long-term growth ...

Neurocrine Biosciences exceeded earnings expectations for Q4 2024, driven by robust sales from key product Ingrezza, while ...

Neurocrine Biosciences, Inc.’s NBIX share price has dipped by 18.53%, which has investors questioning if this is right time ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a ...